iBio, Inc. (NYSEAMERICAN:IBIO – Get Rating) was the target of a large growth in short interest in the month of December. As of December 30th, there was short interest totalling 1,080,000 shares, a growth of 18.2% from the December 15th total of 913,500 shares. Based on an average daily trading volume, of 445,400 shares, the short-interest ratio is currently 2.4 days. Currently, 10.5% of the shares of the company are sold short.
Wall Street Analyst Weigh In
Separately, Cantor Fitzgerald lowered shares of iBio from an “overweight” rating to a “neutral” rating in a report on Thursday, October 6th.
Institutional Trading of iBio
Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in iBio by 7.5% in the 3rd quarter. Vanguard Group Inc. now owns 11,884,917 shares of the biotechnology company’s stock valued at $2,024,000 after purchasing an additional 829,836 shares during the last quarter. BlackRock Inc. raised its position in shares of iBio by 71.7% during the 3rd quarter. BlackRock Inc. now owns 6,799,636 shares of the biotechnology company’s stock worth $1,158,000 after buying an additional 2,838,918 shares in the last quarter. Millennium Management LLC bought a new stake in shares of iBio during the 2nd quarter worth about $1,219,000. Renaissance Technologies LLC raised its position in shares of iBio by 11.9% during the 3rd quarter. Renaissance Technologies LLC now owns 1,287,827 shares of the biotechnology company’s stock worth $219,000 after buying an additional 136,450 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of iBio by 10.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 586,227 shares of the biotechnology company’s stock worth $252,000 after buying an additional 54,084 shares in the last quarter.
iBio Stock Performance
iBio Company Profile
iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates through two segments, Biopharmaceuticals and Bioprocessing. Its lead anti-fibrotic candidate is IBIO-100 for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis.
- Get a free copy of the StockNews.com research report on iBio (IBIO)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.